These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22465225)

  • 1. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
    Kuvaja P; Hulkkonen S; Pasanen I; Soini Y; Lehtonen S; Talvensaari-Mattila A; Pääkkö P; Kaakinen M; Autio-Harmainen H; Hurskainen T; Lehenkari P; Turpeenniemi-Hujanen T
    Exp Cell Res; 2012 Jun; 318(10):1094-103. PubMed ID: 22465225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
    Ree AH; Florenes VA; Berg JP; Maelandsmo GM; Nesland JM; Fodstad O
    Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis.
    Nakopoulou L; Giannopoulou I; Stefanaki K; Panayotopoulou E; Tsirmpa I; Alexandrou P; Mavrommatis J; Katsarou S; Davaris P
    J Pathol; 2002 Jul; 197(3):307-13. PubMed ID: 12115876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases.
    Neri A; Megha T; Bettarini F; Tacchini D; Mastrogiulio MG; Marrelli D; Pinto E; Tosi P
    Hum Pathol; 2012 Aug; 43(8):1184-91. PubMed ID: 22397869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.
    Nakopoulou L; Katsarou S; Giannopoulou I; Alexandrou P; Tsirmpa I; Panayotopoulou E; Mavrommatis J; Keramopoulos A
    Mod Pathol; 2002 Jan; 15(1):26-34. PubMed ID: 11796838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue inhibitor of metalloproteinases-1 in breast cancer.
    Würtz SØ; Schrohl AS; Sørensen NM; Lademann U; Christensen IJ; Mouridsen H; Brünner N
    Endocr Relat Cancer; 2005 Jun; 12(2):215-27. PubMed ID: 15947098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
    Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
    Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer.
    Schoppmann SF; Berghoff A; Dinhof C; Jakesz R; Gnant M; Dubsky P; Jesch B; Heinzl H; Birner P
    Breast Cancer Res Treat; 2012 Jul; 134(1):237-44. PubMed ID: 22350732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome.
    Iwaya K; Ogawa H; Izumi M; Kuroda M; Mukai K
    Virchows Arch; 2002 Jun; 440(6):589-93. PubMed ID: 12070597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
    Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
    Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
    Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
    Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
    Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
    Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of TIMP-1 and nm-23 expressions in HER-2-positive breast cancer].
    Liu J; Yang YF; Fu XL; Yu Y; Gu L
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):600-4. PubMed ID: 23158994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.